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Background
Antibodies PGT141-145 are broadly neutralizing and
recognize a glycan-dependent epitope in the V1/V2 loop,
similar to antibodies PG9 and PG16. Collectively, this
class of antibodies binds preferentially to the functional
viral spike. Although PG9, and to a lesser extent, PG16,
bind monomeric gp120s and V1/V2 scaffolds, to date no
recombinant env-derived proteins have been identified
that bind to antibodies PGT141-145.
Methods
As a first step toward obtaining structural information of
the epitope recognized by PGT141-145, we have created
and characterized novel gp140s and epitope scaffolds
designed to present the V1/V2 conformation recognized
by PGT141-145. To date, over 70 recombinant proteins
have been expressed and tested for antibody binding.
Results
We have identified one V1/V2-scaffold protein that binds
to PGT142. The binding is dependent on the HIV-1 strain
used in the scaffold. We have also produced trimeric,
cleaved gp140 constructs and evaluated them for binding
to PGT141-145.
Conclusion
Proteins that accurately mimic V1/V2 conformations of
the functional viral spike are crucial to obtaining struc-
tures of the PGT antibodies in complex with their epi-
topes, and may be ideal immunogens for eliciting broadly
neutralizing, V1/V2-directed antibodies in a vaccine
setting.
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